High acylglycerol kinase (AGK) expression in glioblastoma correlates with poor prognosis in TCGA patient data. Paradoxically, AGK knockdown inhibits tumor proliferation yet amplifies temozolomide (TMZ) resistance by triggering mitochondrial ROS accumulation, membrane potential collapse, and therapy-induced cellular senescence (CSEN). The senolytic peptide FOXO4-DRI and mitochondrial ROS scavenger Mito-TEMPO each rescued TMZ efficacy by clearing senescent cells via apoptosis, restoring chemosensitivity in cell-based models.
This finding reframes a well-documented liability — therapy-induced senescence — as a targetable resistance mechanism rather than a bystander effect. Glioblastoma's near-universal TMZ resistance has resisted decades of combination strategies; identifying mitochondrial redox signaling through AGK as a senescence rheostat adds mechanistic granularity that prior ROS-focused approaches lacked. The FOXO4-DRI senolytic angle is particularly timely: this peptide has shown proof-of-concept in aging and chemotherapy contexts, and its application here bridges the longevity-oncology interface in a clinically suggestive way. Limitations are substantial, however — findings are confined to cell lines and TCGA correlative data, with no in vivo tumor models presented. The dual role of AGK (suppression simultaneously slows growth but promotes resistance) creates a therapeutic paradox that complicates translation. This is incremental-to-promising mechanistic work that warrants rigorous animal validation before clinical extrapolation, but the senolytic co-targeting framework is conceptually sound and therapeutically actionable.